Bio-Rad Labs (BIO) PT Lowered to $477 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BIO Hot Sheet
Price: $366.16 --0%
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Rating Summary:
9 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 11
Join SI Premium – FREE
RBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $477.00 (from $481.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Hinge Health Inc (HNGE) PT Raised to $134 at Canaccord
- Shenzhen Mindray Bio-Medical Electronics (300760:CH) PT Lowered to RMB233 at JPMorgan
- Varun Beverages Ltd (VBL:IN) PT Lowered to INR490 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
